| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5406 | 2021 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1354 | 2021 |
| Streptococcus pneumoniae: transmission, colonization and invasion JN Weiser, DM Ferreira, JC Paton Nature Reviews Microbiology 16 (6), 355-367, 2018 | 904 | 2018 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 744 | 2021 |
| Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised … X Liu, RH Shaw, ASV Stuart, M Greenland, PK Aley, NJ Andrews, ... The Lancet 398 (10303), 856-869, 2021 | 498 | 2021 |
| Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently of TLR4 EA McNeela, A Burke, DR Neill, C Baxter, VE Fernandes, D Ferreira, ... PLoS pathogens 6 (11), e1001191, 2010 | 418 | 2010 |
| Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) A Flaxman, NG Marchevsky, D Jenkin, J Aboagye, PK Aley, B Angus, ... The Lancet 398 (10304), 981-990, 2021 | 273 | 2021 |
| Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a … ASV Stuart, RH Shaw, X Liu, M Greenland, PK Aley, NJ Andrews, ... The Lancet 399 (10319), 36-49, 2022 | 220 | 2022 |
| Controlled Human Infection and Rechallenge with Streptococcus pneumoniae Reveals the Protective Efficacy of Carriage in Healthy Adults DM Ferreira, DR Neill, M Bangert, JF Gritzfeld, N Green, AKA Wright, ... American journal of respiratory and critical care medicine 187 (8), 855-864, 2013 | 203 | 2013 |
| Inflammation induced by influenza virus impairs human innate immune control of pneumococcus SP Jochems, F Marcon, BF Carniel, M Holloway, E Mitsi, E Smith, ... Nature immunology 19 (12), 1299-1308, 2018 | 157 | 2018 |
| Experimental infection of human volunteers M Roestenberg, MA Hoogerwerf, DM Ferreira, B Mordmüller, ... The Lancet Infectious Diseases 18 (10), e312-e322, 2018 | 155 | 2018 |
| Oxford COVID Vaccine Trial Group Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... Lancet 397 (10269), 99-111, 2021 | 140 | 2021 |
| Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal … DM Ferreira, M Darrieux, DA Silva, LCC Leite, JMC Ferreira Jr, PL Ho, ... Clinical and Vaccine Immunology 16 (5), 636-645, 2009 | 138 | 2009 |
| Experimental human pneumococcal carriage augments IL-17A-dependent T-cell defence of the lung AKA Wright, M Bangert, JF Gritzfeld, DM Ferreira, KC Jambo, AD Wright, ... PLoS pathogens 9 (3), e1003274, 2013 | 119 | 2013 |
| T regulatory cells control susceptibility to invasive pneumococcal pneumonia in mice DR Neill, VE Fernandes, L Wisby, AR Haynes, DM Ferreira, A Laher, ... PLoS pathogens 8 (4), e1002660, 2012 | 115 | 2012 |
| The immunising effect of pneumococcal nasopharyngeal colonisation; protection against future colonisation and fatal invasive disease L Richards, DM Ferreira, EN Miyaji, PW Andrew, A Kadioglu Immunobiology 215 (4), 251-263, 2010 | 114 | 2010 |
| Human alveolar macrophages predominately express combined classical M1 and M2 surface markers in steady state E Mitsi, R Kamng’ona, J Rylance, C Solórzano, J Jesus Reiné, ... Respiratory research 19, 1-4, 2018 | 111 | 2018 |
| Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection AT Moreno, MLS Oliveira, DM Ferreira, PL Ho, M Darrieux, LCC Leite, ... Clinical and Vaccine Immunology 17 (3), 439-446, 2010 | 108 | 2010 |
| Agglutination by anti-capsular polysaccharide antibody is associated with protection against experimental human pneumococcal carriage E Mitsi, AM Roche, J Reiné, T Zangari, JT Owugha, SH Pennington, ... Mucosal immunology 10 (2), 385-394, 2017 | 102 | 2017 |
| Experimental human pneumococcal carriage JF Gritzfeld, AD Wright, AM Collins, SH Pennington, AKA Wright, ... JoVE (Journal of Visualized Experiments), e50115, 2013 | 100 | 2013 |
